CagriSema (cagrilintide + semaglutide)
CagriSema is Novo Nordisk's once-weekly injection that combines semaglutide with cagrilintide, an amylin drug. Its main trial showed about 20% weight loss. It is under FDA review and was not approved when we last checked, in November 2026.
- Legal lane: investigational. Under FDA review; not approved.
- Evidence grade: B. Large Phase 3 trials, not yet approved.
- Form: weekly injection under the skin
- What is in it: cagrilintide 2.4 mg and semaglutide 2.4 mg at the trial target dose
What it is
A fixed combination of two drugs made by the manufacturer: semaglutide, the GLP-1 in Wegovy, and cagrilintide, which acts on the amylin receptor. Unlike the seller blends elsewhere in this library, this combination has been tested as a single product in large trials.
What the evidence shows
In REDEFINE 1, the main trial, average weight loss was 20.4%, or 22.7% counting only people who stayed on treatment. The trial included groups on cagrilintide alone and semaglutide alone, and the combination beat both.
Two results temper that. The 20.4% figure was below what analysts had expected, and a head-to-head trial against tirzepatide, reported in February 2026, was described in coverage as a loss for CagriSema.
Legal status
- Novo Nordisk submitted its application to the FDA on December 18, 2025, based on REDEFINE 1 and REDEFINE 2.
- The company said it expected a decision in the last quarter of 2026. As of early November 2026, no decision had been announced.
- The company has said a US launch is planned for early 2027 if it is approved.
- Until then it cannot be prescribed. The FDA has said cagrilintide cannot be compounded.
This status changes on a single announcement. Check the date on this page.
Reported dosing
No approved dose exists yet.
The Phase 3 trials worked up to a target of 2.4 mg of each drug once a week. If the FDA approves it, the label will set the schedule.
Safety
- Stomach side effects, the same kind seen with semaglutide, were the most common in trials.
- Semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodents. Whether and how that appears on a CagriSema label is for the FDA to decide.
- Anything sold now as CagriSema or as cagrilintide has no regulated source.
Common questions
Is CagriSema FDA-approved?
Not when we last checked, in early November 2026. It was under review, with a decision expected by the end of 2026.
How much weight did people lose on CagriSema?
20.4% on average in the REDEFINE 1 trial, or 22.7% among people who stayed on treatment.
What is in CagriSema?
Cagrilintide and semaglutide, combined in one weekly injection.
Can CagriSema be compounded?
No. The FDA has said cagrilintide cannot be compounded.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.